Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 European drug market entries 2015 with new mechanisms of action.

Literature DB >> 27697814

European drug market entries 2015 with new mechanisms of action.

Titus W P van den Heuvel¹, Adam F Cohen², Robert Rissmann³.

Abstract

In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma. © Royal College of Physicians 2016. All rights reserved.

Entities: Chemical Disease Gene

Keywords: Pharmacology; asthma; drug mechanisms; first in class; heart failure; hypercholesterolaemia; market approval

Mesh：

Substances：

Year: 2016 PMID： 27697814 PMCID： PMC6297309 DOI： 10.7861/clinmedicine.16-5-475

Source DB: PubMed Journal: Clin Med (Lond) ISSN： 1470-2118 Impact factor: 2.659

11 in total

Review 1. The PCSK9 decade.

Authors: Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal: J Lipid Res Date: 2012-07-17 Impact factor: 5.922

2. The immunology of asthma.

Authors: Bart N Lambrecht; Hamida Hammad
Journal: Nat Immunol Date: 2015-01 Impact factor: 25.606

Review 3. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

Authors: Elisabeth H Bel; Ana Sousa; Louise Fleming; Andrew Bush; K Fan Chung; Jennifer Versnel; Ariane H Wagener; Scott S Wagers; Peter J Sterk; Chris H Compton
Journal: Thorax Date: 2010-11-23 Impact factor: 9.139

Review 4. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.

Authors: Eugene Braunwald
Journal: J Am Coll Cardiol Date: 2015-03-17 Impact factor: 24.094

Review 5. Targeting eosinophils in allergy, inflammation and beyond.

Authors: Patricia C Fulkerson; Marc E Rothenberg
Journal: Nat Rev Drug Discov Date: 2013-01-21 Impact factor: 84.694

6. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245

7. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Authors: Milton Packer; Robert M Califf; Marvin A Konstam; Henry Krum; John J McMurray; Jean-Lucien Rouleau; Karl Swedberg
Journal: Circulation Date: 2002-08-20 Impact factor: 29.690

1. Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.

Authors: Kathleen A Fairman; Lindsay E Davis; David A Sclar
Journal: Ther Clin Risk Manag Date: 2017-08-03 Impact factor: 2.423

1 in total